Metabolomics analyses reveal the crucial role of ERK in regulating metabolic pathways associated with the proliferation of human cutaneous T-cell lymphoma cells treated with Glabridin

Abstract

Cutaneous T-cell lymphomas (CTC) are a heterogeneous group of T-cell lymphoproliferative malignancies of the skin with limited treatment options, increased resistance and remission. Metabolic reprogramming is vital in orchestrating the uncontrolled growth and proliferation of cancer cells. Importantly, deregulated signalling plays a significant role in metabolic reprogramming. Considering the crucial role of metabolic reprogramming in cancer-cell growth and proliferation, target identification and the development of novel and multi-targeting agents are imperative. The present study explores the underlying mechanisms and metabolic signalling pathways associated with Glabridin mediated anti-cancer actions in CTCL. Our results show that Glabridin significantly inhibits the growth of CTCL cells through induction of programmed cell death (PCD) such as apoptosis, autophagy and necrosis. Interestingly, results further show that Glabridin induces PCD in CTCL cells by targeting MAPK signalling pathways, particularly the activation of ERK. Further, Glabridin also sensitized CTCL cells to the anti-cancer drug, bortezomib. Importantly, LC–MS-based metabolomics analyses further showed that Glabridin targeted multiple metabolites and metabolic pathways intricately involved in cancer cell growth and proliferation in an ERK-dependent fashion. Overall, our findings revealed that Glabridin induces PCD and attenuates the expression of regulatory proteins and metabolites involved in orchestrating the uncontrolled proliferation of CTCL cells through ERK activation. Therefore, Glabridin possesses important features of an ideal anti-cancer agent.

References

[1] LiuX, JinS, HuS, et al. Single-cell transcriptomics links malignant T cells to the tumor immune landscape in cutaneous T cell lymphoma. Nat Commun. 2022; 13(1):1158. doi:10.1038/s41467-022-28799-3

[2] HanahanD, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-674.

[3] WangW, ZouW. Amino acids and their transporters in T cell immunity and cancer therapy. Mol Cell. 2020; 80(3):384-395.

[4] XiongJ, BianJ, WangL, et al. Dysregulated choline metabolism in T-cell lymphoma: role of choline kinase-α and therapeutic targeting. Blood Cancer J. 2015; 5(3):287.

[5] YakymivY, Marchisio S, OrtolanE, et al. CD39/CD73 dysregulation and adenosine metabolism contribute to T-cell immunosuppression in patients with Sézary syndrome. Blood. 2023; 141(1):111-116.

[6] MondalD, ShindeS, PaulS, et al. Diagnostic significance of dysregulated miRNAs in T-cell malignancies and their metabolic roles. Front Oncol. 2023; 13:1230273.

[7] Yoshida-SakaiN, Watanabe T, YamamotoY, et al. Adult T-cell leukemia-lymphoma acquires resistance to DNA demethylating agents through dysregulation of enzymes involved in pyrimidine metabolism. Int J Cancer. 2022; 150(7):1184-1197.

[8] KhanMA, ZubairH, AnandS, Srivastava SK, SinghS, SinghAP. Dysregulation of metabolic enzymes in tumor and stromal cells: role in oncogenesis and therapeutic opportunities. Cancer Lett. 2020; 473:176-185.

[9] OsmanAA, ArslanE, BartelsM, et al. Dysregulation and epigenetic reprogramming of NRF2 signaling axis promote acquisition of cisplatin resistance and metastasis in head and neck squamous cell carcinoma. Clin Cancer Res. 2023; 29(7):1344-1359.

[10] AslER, AminiM, NajafiS, et al. Interplay between MAPK/ERK signaling pathway and MicroRNAs: a crucial mechanism regulating cancer cell metabolism and tumor progression. Life Sci. 2021; 278:119499.

[11] SmithLK, RaoAD, McArthurGA. Targeting metabolic reprogramming as a potential therapeutic strategy in melanoma. Pharmacol Res. 2016; 107:42-47.

[12] HargadonKM. Genetic dysregulation of immunologic and oncogenic signaling pathways associated with tumor-intrinsic immune resistance: a molecular basis for combination targeted therapy-immunotherapy for cancer. Cell Mol Life Sci. 2023; 80(2):40.

[13] MishraSK, Millman SE, ZhangL. Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets. Blood. 2023; 141(10):1119-1135.

[14] PavlovaNN, ZhuJ, ThompsonCB. The hallmarks of cancer metabolism: still emerging. Cell Metab. 2022; 34(3):355-377.

[15] IntlekoferAM, FinleyLWS. Metabolic signatures of cancer cells and stem cells. Nat Metab. 2019; 1(2):177-188.

[16] MalayilR, Chhichholiya Y, VasudevaK, et al. Oncogenic metabolic reprogramming in breast cancer: focus on signaling pathways and mitochondrial genes. Med Oncol. 2023; 40(6):174.

[17] XiangH, YangR, TuJ, et al. Metabolic reprogramming of immune cells in pancreatic cancer progression. Biomed Pharmacother. 2023; 157:113992.

[18] ArnerEN, Rathmell JC. Metabolic programming and immune suppression in the tumor microenvironment. Cancer Cell. 2023; 41(3):421-433.

[19] LiY-J, ZhangC, MartincuksA, Herrmann A, YuH. STAT proteins in cancer: orchestration of metabolism. Nat Rev Cancer. 2023; 23(3):115-134.

[20] HoxhajG, Manning BD. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 2020; 20(2):74-88.

[21] El-SahliS, WangL. Cancer stem cell-associated pathways in the metabolic reprogramming of breast cancer. Int J Mol Sci. 2020; 21(23):9125.

[22] PapaS, ChoyPM, BubiciC. The ERK and JNK pathways in the regulation of metabolic reprogramming. Oncogene. 2019; 38(13):2223-2240.

[23] NwosuZC, Piorońska W, BattelloN, et al. Severe metabolic alterations in liver cancer lead to ERK pathway activation and drug resistance. EBioMedicine. 2020; 54:102699.

[24] ZhangJ, WuX, ZhongB, et al. Review on the diverse biological effects of Glabridin. Drug Des Devel Ther. 2023; 17:15-37.

[25] LinH, AiD, LiuQ, et al. Natural isoflavone Glabridin targets PI3Kγ as an adjuvant to increase the sensitivity of MDA-MB-231 to tamoxifen and DU145 to paclitaxel. J Steroid Biochem Mol Biol. 2024; 236:106426.

[26] SimmlerC, PauliGF, ChenS-N. Phytochemistry and biological properties of Glabridin. Fitoterapia. 2013; 90:160-184.

[27] ChangJ, WangL, ZhangM, Lai Z. Glabridin attenuates atopic dermatitis progression through downregulating the TLR4/MyD88/NF-κB signaling pathway. Genes Genomics. 2021; 43(8):847-855.

[28] PengG, LiY, ZengY, Sun B, ZhangL, LiuQ. Effect of Glabridin combined with bakuchiol on UVB-induced skin damage and its underlying mechanism: an experimental study. J Cosmet Dermatol. 2024; 23:2256-2269.

[29] LiD, FanJ, DuL, RenG. Prenylated flavonoid fractions from Glycyrrhiza glabra alleviate insulin resistance in HepG2 cells by regulating the ERK/IRS-1 and PI3K/Akt signaling pathways. Arch Pharm Res. 2024; 47(2):127-145.

[30] Al-TamimiM, KhanAQ, AnverR, et al. Pristimerin mediated anticancer effects and sensitization of human skin cancer cells through modulation of MAPK signaling pathways. Biomed Pharmacother. 2022; 156:113950.

[31] HishinumaE, Shimada M, MatsukawaN, et al. Wide-targeted metabolome analysis identifies potential biomarkers for prognosis prediction of epithelial ovarian cancer. Toxins (Basel). 2021; 13(7):461.

[32] PangZ, LuY, ZhouG, et al. MetaboAnalyst 6.0: towards a unified platform for metabolomics data processing, analysis and interpretation. Nucleic Acids Res. 2024: gkae253. doi:10.1093/nar/gkae253

[33] HuangH-L, HsiehM-J, ChienM-H, Chen H-Y, YangS-F, HsiaoP-C. Glabridin mediate caspases activation and induces apoptosis through JNK1/2 and p38 MAPK pathway in human promyelocytic leukemia cells. PLoS One. 2014; 9(6):e98943.

[34] ZhuK, LiK, WangH, Kang L, DangC, ZhangY. Discovery of Glabridin as potent inhibitor of epidermal growth factor receptor in SK-BR-3 cell. Pharmacology. 2019; 104(3–4):113-125.

[35] CuiX, CuiM. Glabridin induces paraptosis-like cell death via ER stress in breast cancer cells. Heliyon. 2022; 8(9):e10607.

[36] ChenC-T, ChenY-T, HsiehY-H, et al. Glabridin induces apoptosis and cell cycle arrest in oral cancer cells through the JNK1/2 signaling pathway. Environ Toxicol. 2018; 33(6):679-685.

[37] SuZ, YangZ, XuY, ChenY, YuQ. Apoptosis, autophagy, necroptosis, and cancer metastasis. Mol Cancer. 2015; 14:48.

[38] JiangF, LiY, MuJ, et al. Glabridin inhibits cancer stem cell-like properties of human breast cancer cells: an epigenetic regulation of miR-148a/SMAd2 signaling. Mol Carcinog. 2016; 55(5):929-940.

[39] WangZ, LuoS, WanZ, et al. Glabridin arrests cell cycle and inhibits proliferation of hepatocellular carcinoma by suppressing braf/MEK signaling pathway. Tumour Biol. 2016; 37(5):5837-5846.

[40] StineZE, SchugZT, SalvinoJM, Dang CV. Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discov. 2022; 21(2):141-162.

[41] LiuK, PiF, ZhangH, et al. Metabolomics analysis to evaluate the anti-inflammatory effects of polyphenols: Glabridin reversed metabolism change caused by LPS in RAW 264.7 cells. J Agric Food Chem. 2017; 65(29):6070-6079.

[42] LieuEL, NguyenT, RhyneS, Kim J. Amino acids in cancer. Exp Mol Med. 2020; 52(1):15-30.

[43] PompeiaC, LimaT, CuriR. Arachidonic acid cytotoxicity: can arachidonic acid be a physiological mediator of cell death? Cell Biochem Funct. 2003; 21(2):97-104.

[44] LappanoR, Sebastiani A, CirilloF, et al. The lauric acid-activated signaling prompts apoptosis in cancer cells. Cell Death Discov. 2017; 3:17063.

[45] D’EliseoD, Velotti F. Omega-3 fatty acids and cancer cell cytotoxicity: implications for multi-targeted cancer therapy. J Clin Med. 2016; 5(2):15.

[46] WangJ, ChenY, SongQ, Griffiths A, SongZ. mTORC1-IRE1α pathway activation contributes to palmitate-elicited triglyceride secretion and cell death in hepatocytes. Exp Biol Med (Maywood). 2020; 245(14):1268-1279.

[47] HenryB, Möller C, Dimanche-BoitrelM-T, GulbinsE, BeckerKA. Targeting the ceramide system in cancer. Cancer Lett. 2013; 332(2):286-294.

[48] MoradSAF, CabotMC. Ceramide-orchestrated signalling in cancer cells. Nat Rev Cancer. 2013; 13(1):51-65.

[49] WajapeyeeN, BeamonTC, GuptaR. Roles and therapeutic targeting of ceramide metabolism in cancer. Mol Metab. 2024; 83:101936.

[50] GlundeK, PenetM-F, JiangL, Jacobs MA, BhujwallaZM. Choline metabolism-based molecular diagnosis of cancer: an update. Expert Rev Mol Diagn. 2015; 15(6):735-747.

[51] GlundeK, Bhujwalla ZM, RonenSM. Choline metabolism in malignant transformation. Nat Rev Cancer. 2011; 11(12):835-848.

[52] PucciS, FasoliF, MorettiM, et al. Choline and nicotine increase glioblastoma cell proliferation by binding and activating α7- and α9-containing nicotinic receptors. Pharmacol Res. 2021; 163:105336.

[53] HsuC-C, PengD, CaiZ, LinH-K. AMPK signaling and its targeting in cancer progression and treatment. Semin Cancer Biol. 2022; 85:52-68.

[54] SteinbergGR, HardieDG. New insights into activation and function of the AMPK. Nat Rev Mol Cell Biol. 2023; 24(4):255-272.

[55] SadriaM, SeoD, LaytonAT. The mixed blessing of AMPK signaling in cancer treatments. BMC Cancer. 2022; 22(1):105.

[56] JeonS-M, HayN. The double-edged sword of AMPK signaling in cancer and its therapeutic implications. Arch Pharm Res. 2015; 38(3):346-357.

[57] AshrafizadehM, Mirzaei S, HushmandiK, et al. Therapeutic potential of AMPK signaling targeting in lung cancer: advances, challenges and future prospects. Life Sci. 2021; 278:119649.

[58] PengB, ZhangS-Y, ChanKI, Zhong Z-F, WangY-T. Novel anti-cancer products targeting AMPK: natural herbal medicine against breast cancer. Molecules. 2023; 28(2):740.

[59] JeonS-M, Chandel NS, HayN. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature. 2012; 485(7400):661-665.

[60] WangZ, WangN, LiuP, XieX. AMPK and cancer. Exp Suppl. 2016; 107:203-226. doi:10.1007/978-3-319-43589-3_9

[61] ViolletB, HormanS, LeclercJ, et al. AMPK inhibition in health and disease. Crit Rev Biochem Mol Biol. 2010; 45(4):276-295.

[62] HuM, ChenX, MaL, et al. AMPK inhibition suppresses the malignant phenotype of pancreatic cancer cells in part by attenuating aerobic glycolysis. J Cancer. 2019; 10(8):1870-1878.

[63] JiaJ, JiW, SalibaAN, et al. AMPK inhibition sensitizes acute leukemia cells to BH3 mimetic-induced cell death. Cell Death Differ. 2024; 31(4):405-416.

[64] SlaninovaV, Krafcikova M, Perez-GomezR, et al. Notch stimulates growth by direct regulation of genes involved in the control of glycolysis and the tricarboxylic acid cycle. Open Biol. 2016; 6(2):150155.

[65] SellersK, AllenTD, BousamraM, et al. Metabolic reprogramming and Notch activity distinguish between non-small cell lung cancer subtypes. Br J Cancer. 2019; 121(1):51-64.

[66] LeeJV, CarrerA, ShahS, et al. Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation. Cell Metab. 2014; 20(2):306-319.

[67] DongY, TuR, LiuH, QingG. Regulation of cancer cell metabolism: oncogenic MYC in the driver’s seat. Signal Transduct Target Ther. 2020; 5(1):124.

RIGHTS & PERMISSIONS

2024 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.